Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
26 studies found for:    "Hemosiderosis"
Show Display Options
Rank Status Study
1 Completed Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox
Condition: Transfusional Hemosiderosis
Intervention: Drug: deferasirox
2 Not yet recruiting Efficacy of Bone Marrow Mesenchymal Stem Cell in Pulmonary Hemosiderosis
Condition: Idiopathic Pulmonary Hemosiderosis
Intervention: Biological: Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis
3 Completed Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Conditions: Chronic Anemia;   Transfusional Hemosiderosis
Intervention: Drug: Deferasirox (ICL670)
4 Completed A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis
Conditions: Beta-Thalassemia;   Hemosiderosis
Intervention: Drug: deferasirox
5 Completed Pharmacogenetic Study in Patients Received Iron Chelating Agent
Condition: Hemosiderosis
Intervention:
6 Completed Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food
Condition: Transfusional Hemosiderosis
Intervention: Drug: deferasirox:
7 Completed Safety, Tolerability, and Efficacy of Deferasirox in MDS
Conditions: Myelodysplastic Syndromes;   Hemosiderosis
Intervention: Drug: Deferasirox
8 Completed
Has Results
Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
Conditions: Beta-thalassemia Major;   Hemosiderosis;   Iron Overload;   Rare Anemia
Intervention: Drug: Deferasirox
9 Completed Non-invasive Quantification of Liver Iron With MRI
Conditions: Iron Overload;   Hemosiderosis
Intervention: Device: Non-contrast MRI
10 Completed
Has Results
Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload
Conditions: Transfusional Iron Overload;   Transfusional Hemosiderosis
Interventions: Drug: Core Study: Deferasirox;   Drug: Core Study: Deferoxamine;   Drug: Extension: deferoxamine to deferasirox;   Drug: Extension: deferasirox to deferoxamine;   Drug: Deferasirox;   Drug: Deferoxamine
11 Completed Efficacy Study in Removing Excess Iron From the Heart
Conditions: Thalassemia Major;   Hemosiderosis
Interventions: Drug: Ferriprox (deferiprone);   Drug: Desferal (deferoxamine)
12 Not yet recruiting Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis
Conditions: Amyloid Cerebral Angiopathy;   Alzheimer Disease
Interventions: Device: Pet scan with FBB;   Device: MRI scan;   Biological: APO E genotyping
13 Completed
Has Results
Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients
Conditions: Anemia;   Hemosiderosis
Intervention: Drug: Deferasirox
14 Completed Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions
Condition: Beta-Thalassemia
Interventions: Drug: ICL670;   Drug: deferoxamine
15 Recruiting Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron Content
Conditions: Iron Overload;   Hemochromatosis;   Hemosiderosis
Intervention: Other: MRI
16 Completed Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions
Condition: Anemia, Sickle Cell
Intervention: Drug: ICL670, deferoxamine
17 Unknown  Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload
Conditions: Beta-thalassemia Major;   Sickle Cell Disease;   Iron Hemosiderosis
Interventions: Drug: DFP (ferriprox) and deferasirox (ICL 670);   Drug: DFP, DFO
18 Completed ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
Condition: Anemia
Intervention: Drug: Deferasirox
19 Completed Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias
Conditions: Beta-thalassemia;   Myelodysplastic Syndromes;   Fanconi Syndrome;   Anemia, Diamond-Blackfan;   Anemia, Aplastic
Intervention: Drug: Deferasirox
20 Withdrawn Treatment of Iron Overload Requiring Chelation Therapy
Conditions: Transfusional Iron Overload;   Iron Overload;   Iron Chelation;   Beta-thalassemia;   Transfusional Hemosiderosis;   Iron Metabolism Disorders;   Metabolic Diseases
Interventions: Drug: SPD602;   Drug: Deferasirox

   Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.